RCMNY
CHRS icon

Rubric Capital Management (New York)’s Coherus Oncology CHRS Stock Holding History

Rubric Capital Management (New York)’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-350,000
Closed -$4.9M – 53
2018
Q2 		$4.9M Buy
+350,000
New +$5.01M 0.48% 31

Other funds holding CHRS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Rubric Capital Management (New York)'s CHRS Position: Q3 2025 in Review

Rubric Capital Management (New York) sold out of Coherus Oncology (CHRS) in Q3 2025, closing a stake of 867,800 shares — an estimated $635K sold.

Rubric Capital Management (New York) first reported a position in CHRS in Q1 2018 and held it in 16 quarters. The position peaked at $41.3M in Q3 2019. 114 funds tracked by Wall St. Rank hold CHRS as of Q3 2025.

  • Rubric Capital Management (New York) reported no remaining Coherus Oncology position as of Q3 2025 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 867,800 Coherus Oncology shares in Q3 2025, an estimated $635K.
  • Rubric Capital Management (New York) first reported a position in Coherus Oncology in Q1 2018 and held it in 16 quarters.
  • Rubric Capital Management (New York)'s Coherus Oncology position peaked at $41.3M in Q3 2019.
  • 114 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2025, filed 14 Nov 2025.